{"entity":{"id":"karim-fizazi","kind":"person","name":"Karim Fizazi","aka":[],"tldr":"Led LATITUDE and PEACE-1, which put abiraterone into first-line metastatic prostate cancer.","summary":"Karim Fizazi is Head of Medical Oncology at Gustave Roussy and Professor at Paris-Saclay, with links to Centre Oscar Lambret. His specialisms are prostate cancer, genitourinary oncology, hormone therapy and radioligand therapy. He is one of the most influential prostate cancer trialists of the past two decades, leading LATITUDE, the New England Journal of Medicine trial of abiraterone plus prednisone in high-risk metastatic castration-sensitive prostate cancer, and PEACE-1, the Lancet trial adding abiraterone to androgen deprivation therapy and docetaxel in de novo metastatic disease. He has also led studies of radium-223 and PSMA radioligands, and is linked to the ALSYMPCA trial. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fizazi%20K%5BAuthor%5D%20prostate%20abiraterone"}],"tags":[],"related":["ra-223"],"indications":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["abiraterone","radium-223"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["alsympca"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Medical Oncology, Gustave Roussy; Professor, Paris-Saclay","specialisms":["Prostate cancer","Genitourinary oncology","Hormone therapy","Radioligand therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fizazi%20K%5BAuthor%5D%20prostate%20abiraterone"}],"papers":[{"title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer (LATITUDE)","journal":"NEJM","year":2017,"doi":"10.1056/NEJMoa1704174"},{"title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1)","journal":"Lancet","year":2022,"doi":"10.1016/S0140-6736(22)00367-1"},{"title":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2107322","doi":"10.1056/NEJMoa2107322"},{"title":"ARAMIS: darolutamide in non-metastatic castration-resistant prostate cancer","journal":"New England Journal of Medicine","year":2019,"url":"https://doi.org/10.1056/NEJMoa1815671","doi":"10.1056/NEJMoa1815671"}]},"route":"/people/karim-fizazi/","neighbours":{"isotope":[{"id":"ra-223","kind":"isotope","name":"Radium-223","route":"/isotopes/ra-223/"}],"indication":[{"id":"prostate","kind":"indication","name":"Prostate cancer","route":"/indications/prostate/"}],"drug":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/"},{"id":"radium-223","kind":"drug","name":"Radium-223 dichloride","route":"/drugs/radium-223/"}],"trial":[{"id":"alsympca","kind":"trial","name":"ALSYMPCA","route":"/trials/alsympca/"}],"paper":[{"id":"paper-psmafore-lancet-2024","kind":"paper","name":"PSMAfore: 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor in taxane-naive mCRPC","route":"/key-papers/paper-psmafore-lancet-2024/"},{"id":"paper-vision-nejm-2021","kind":"paper","name":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer","route":"/key-papers/paper-vision-nejm-2021/"}],"pairing":[{"id":"radium223-abiraterone-caution","kind":"pairing","name":"Radium-223 with abiraterone: a caution, not a combination","route":"/pairings/radium223-abiraterone-caution/"}]}}